Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Eterna Therapeutics ( (ERNA) ) is now available.
On March 18, 2026, Ernexa Therapeutics Inc. received notice from Nasdaq that its common stock failed to maintain the required minimum bid price of $1.00 per share for 30 consecutive business days, breaching Listing Rule 5550(a)(2). Because Ernexa conducted a reverse stock split within the prior year, it is not eligible for the standard 180-day grace period to regain compliance under Nasdaq rules.
The company will request a hearing before a Nasdaq Hearings Panel, which will stay any suspension or delisting action while the process is pending, and the panel may grant an extension of up to 180 days from the date of the notice. Ernexa plans to present a remediation strategy to restore compliance, but it warned investors there is no assurance the panel will rule in its favor or that its securities will remain listed on the Nasdaq Capital Market.
More about Eterna Therapeutics
Ernexa Therapeutics Inc. is a Delaware-incorporated company whose common stock is listed on the Nasdaq Capital Market. The company’s shares are subject to Nasdaq’s minimum bid price and other continued listing requirements that govern eligibility to remain on the exchange.
Average Trading Volume: 1,592,111
Technical Sentiment Signal: Strong Sell
Current Market Cap: $7.87M
For a thorough assessment of ERNA stock, go to TipRanks’ Stock Analysis page.